title: Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer.
abstract: BACKGROUND
  The purpose of this study was to investigate the prognostic significance of serum sCD163 in patients with epithelial ovarian cancer.
  
  
  METHODS
  Preoperative serum samples from 55 patients with epithelial ovarian cancers were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay kit. A Cox proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for disease-free survival (DFS) and overall survival (OS).
  
  
  RESULTS
  Median serum sCD163 levels were higher in patients with a high-grade tumor. High serum sCD163 levels (3.43 mg/l) were associated with poor prognostic factors such as advanced stage (p = 0.024) and positive peritoneal cytology (p = 0.015). Univariate survival analysis showed that elevated sCD163 levels were associated with short DFS (8.0 vs. 32.4 months, p = 0.04) and OS (19.7 vs. 40.0 months, p = 0.027). Multivariate survival analysis revealed that high serum sCD163 levels were negatively associated with DFS (HR 3.1, 95% CI 1.2-8.1, p = 0.039).
  
  
  CONCLUSIONS
  Our study shows that elevated serum sCD163 levels were associated with poor prognosis in patients with ovarian cancer.
  
  
  CONCLUSIONS
  The prognostic significance of serum sCD163 in patients with epithelial ovarian cancer is described.
authors.affiliation: Department of Obstetrics and Gynecology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
authors.forename: Jae Hong
authors.initials: JH
authors.lastname: No
authors.forename: Jeong Min
authors.initials: JM
authors.lastname: Moon
authors.forename: Kidong
authors.initials: K
authors.lastname: Kim
authors.forename: Yong-Beom
authors.initials: YB
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000097:blood*; D015214:Antigens, Differentiation, Myelomonocytic / Q000097:blood*; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D015999:Multivariate Analysis; D009375:Neoplasms, Glandular and Epithelial / Q000378:metabolism* / Q000401:mortality*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000401:mortality*; D011379:Prognosis; D016016:Proportional Hazards Models; D011956:Receptors, Cell Surface / Q000097:blood*; D012307:Risk Factors; D012995:Solubility; D000098902:CD163 Antigen
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D000098902:CD163 Antigen; D011956:Receptors, Cell Surface